US Stock Market Move | The acquisition of Verve Therapeutics (VERV.US) for 1.3 billion USD at a premium of 130% has caused its stock to surge over 74%.

On Tuesday, Verve Therapeutics (VERV.US) surged over 74%, reaching $10.99. According to media reports, global pharmaceutical giant Gilead Sciences is preparing to acquire the gene editing startup Verve Therapeutics for up to $1.3 billion, with $1 billion as an upfront payment and an additional $300 million based on specific clinical milestones achieved by Verve. This is undoubtedly a very attractive deal for Verve.